Results 11 to 20 of about 4,653 (155)

Superior effect of allopurinol compared to febuxostat on the retardation of chronic kidney disease progression

PLoS ONE, 2022
Background Although hyperuricemia is associated with chronic kidney disease, whether and how it should be managed for renoprotection remains debatable.
Seokwoo Park, Jung Pyo Lee, Dong Ki Kim, Yon Su Kim, Chun Soo Lim   +4 more
doaj   +3 more sources

Febuxostat: a new drug for an old disease. Do we really need it?

Italian Journal of Medicine, 2013
BACKGROUND Febuxostat is a non-purine selective inhibitor of xanthine oxidase whose therapeutic effect is decreasing the serum uric acid concentration.
Giovanni Gulli, Luigi de Filippis
doaj   +1 more source

Impact of urate-lowering therapy on quality of life indicators in patients with gout

Современная ревматология, 2021
Gout can have a significant impact on the quality of life (QoL) of patients.Objective: to assess the dynamics of QoL indicators and the possibility of achieving the target level of uric acid (UA) in patients with gout on febuxostat therapy, with ...
M. N. Chikina, O. V. Zhelyabina, M. S. Eliseev   +2 more
doaj   +1 more source

The current treatment strategy for gouty arthritis

Современная ревматология, 2018
Febuxostat is a non-purine selective inhibitor of isoforms of xanthine oxidoreductase (XOR), the effect of which is aimed at lowering the level of serum uric acid (UA).
M. S. Petrova, М. M. Musiychuk, V. I. Mazurov   +2 more
doaj   +1 more source

Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study

Therapeutic Advances in Musculoskeletal Disease, 2022
Background: To evaluate the safety, tolerability, and efficacy of SHR4640, a highly selective urate transporter-1 inhibitor, in combination with febuxostat, in patients with primary hyperuricemia.
Honghu Tang, Beibei Cui, Yiyu Chen, Lin Chen, Zhihong Wang, Ning Zhang, Yanlan Yang, Xiaodong Wang, Xiangliang Xie, Lingyun Sun, Wantai Dang, Xianyang Wang, Runzi Li, Jianjun Zou, Yi Zhao, Yi Liu   +15 more
doaj   +1 more source

Evaluation of analgesic activity of allopurinol and febuxostat in experimental analgesic models in mice

Indian Journal of Pain, 2015
Background: Allopurinol and febuxostat are xanthine oxidase inhibitors which are used in the treatment of hyperuricemia and gout. Pain is one of the important symptoms in gout patients.
Promod D Shankpal, J H Hotwani, Kunal A Chitnis, Dnyanesh S Tadke, Vijay R Kokani   +4 more
doaj   +1 more source

Combination of Panax ginseng C. A. Mey and Febuxostat Boasted Cardioprotective Effects Against Doxorubicin-Induced Acute Cardiotoxicity in Rats

Frontiers in Pharmacology, 2022
Doxorubicin (DOX) is an anticancer agent for treating solid and soft tissue malignancies. However, the clinical use of DOX is restricted by cumulative, dose-dependent cardiotoxicity.
Hayder M. Al-Kuraishy, Hany A. Al-Hussaniy, Ali I. Al-Gareeb, Walaa A. Negm, Aya H. El-Kadem, Gaber El-Saber Batiha, Nermeen N. Welson, Gomaa Mostafa-Hedeab, Gomaa Mostafa-Hedeab, Ahmed H Qasem, Carlos Adam Conte-Junior   +10 more
doaj   +1 more source

Comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults: a propensity-matched analysis

Arthritis Research & Therapy, 2018
Background The purpose of this study was to assess the comparative effectiveness of allopurinol versus febuxostat for preventing incident dementia in older adults.
Jasvinder A. Singh, John D. Cleveland
doaj   +1 more source

Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease

Scientific Reports, 2023
Hyperuricemia relates to chronic kidney disease (CKD) progression and impaired endothelial function. Febuxostat is potent and effective for decreasing serum uric acid levels.
Naowanit Nata, Nanthawut Ninwisut, Pitchamon Inkong, Ouppatham Supasyndh, Bancha Satirapoj   +4 more
doaj   +1 more source

Efficacy and Safety of Different Doses of Urico-Lowering Agents in The Treatment of Gout with Hyperuricemia: A Systematic Review and Network Meta-Analysis [PDF]

BIO Web of Conferences
Objectives: To systematically evaluate the efficacy and safety of different doses of uric acid- lowering drugs (allopurinol, febuxostat, and benzbromarone) in patients with gout with hyperuricemia by using the method of reticulated Meta-analysis. Methods:
Wen Jie, Wang Yongyan, Li Jialin, Zhang Yiying, Shi Yan, Li Xingzhou, Sun Xuewei   +6 more
doaj   +1 more source